New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review.
10.19746/j.cnki.issn.1009-2137.2021.02.052
- Author:
Bei-Ni HU
1
;
Xiang YANG
1
;
Yong-Ping YUAN
1
;
Yi-Jian CHEN
2
Author Information
1. Gannan Medical College, Ganzhou 341000, Jiangxi Province, China.
2. Department of Hematology, The First Affiliated Hospital of Gannan Medical College, Ganzhou 341000, Jiangxi Province, China,E-mail: chenyj2005@163.com.
- Publication Type:Review
- MeSH:
Aged;
Antineoplastic Combined Chemotherapy Protocols;
Central Nervous System;
Central Nervous System Neoplasms/drug therapy*;
Humans;
Lymphoma, Non-Hodgkin/drug therapy*;
Neoplasm Recurrence, Local;
Phosphatidylinositol 3-Kinases
- From:
Journal of Experimental Hematology
2021;29(2):633-637
- CountryChina
- Language:Chinese
-
Abstract:
Primary central nervous system lymphoma (PCNSL) is a rare aggressive non-Hodgkin's lymphoma outside the lymph nodes. At present, high-dose chemotherapy based on methotrexate is the standard induction therapy for newly diagnosed PCNSL, but the effective therapy of relapse/refractory and elderly PCNSL is still unclear. With the progress of clinical trials, new drugs and combined treatment method appear constantly, such as rituximab and ibrutinib, the remission rate of refractory and relapsed patients increased, while lenalidomide showed a good activity in the maintenance treatment of elderly patients. This review summarized briefly the recent advances of research on immunocheckpoint inhibitors, immunoregulatory agents, bruton tyrosine kinase (BTK) and PI3K/AKT/mTOR pathway inhibitors.
